Abbvie SA
213.4 FTEAbbvie reported revenue of €265.6m for the 2025 financial year (annual accounts filed with the NBB on 08 Jun 2026), with 213.4 full-time equivalents.
The score of Abbvie shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Revenue +54 % Equity -3 % Total assets 0 %
Accounts of the company itself (not consolidated).
The full file covers 8 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Abbvie's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 08 Jun 2026
- Year ended 31 Dec 2024filed on 17 Jun 2025
- Year ended 31 Dec 2023filed on 07 Jun 2024
- Year ended 31 Dec 2022filed on 12 Jun 2023
- Year ended 31 Dec 2021filed on 09 Jun 2022
Abbvie's financial analysis
- Solvency80.4%sector median: 43.9%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Abbvie
Abbvie's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0845.096.860
- VAT number
- BE0845096860
- Peppol
- Registered · 0208:0845096860 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 05 Apr 2012
- Registered office
- 1300 Wavre
- Size
- Medium · 213.4 FTE
- Latest accounts
- 2025 · filed on 08 Jun 2026
- Activity
- Wholesale of pharmaceutical and medical goods (NACE 46460)
Abbvie (SA) has been based in Wavre since 2012, active in: wholesale of pharmaceutical and medical goods. For 2025, it reports revenue of €265.6m, a net profit of €6.45m and equity of €182.7m. With 213.4 full-time equivalents, it is a medium-sized enterprise by headcount. Its solvency stands at 80.4%, above the median of its sector (43.9%).
Companies similar to Abbvie
Companies in the same business, of comparable size and area, outside its group.
- UPSA Belgium Wholesale of pharmaceutical and medical goods Etterbeek · balance sheet €104.2m
- Gilead Sciences Belgium Wholesale of pharmaceutical and medical goods Machelen (Brab.) · balance sheet €68.7m
- sandoz Wholesale of pharmaceutical and medical goods Machelen (Brab.) · balance sheet €55.3m
- O&M Halyard Belgium Wholesale of pharmaceutical and medical goods Machelen (Brab.) · balance sheet €45.9m
- Sanofi Belgium Wholesale of pharmaceutical and medical goods Machelen (Brab.) · balance sheet €218.9m
- B. Braun Medical Wholesale of pharmaceutical and medical goods Machelen (Brab.) · balance sheet €22.6m
- MED Concept Europe Wholesale of pharmaceutical and medical goods Woluwe-Saint-Pierre · balance sheet €18.7m
- Elekta Wholesale of pharmaceutical and medical goods Zaventem · balance sheet €13.1m
Frequently asked questions about Abbvie
What is the revenue of Abbvie?
According to the 2025 annual accounts filed with the NBB, the revenue of Abbvie amounts to 265,550,630 €.
What is the VAT number of Abbvie?
In Belgium, the VAT number is the company number prefixed with BE: BE0845096860 for Abbvie, if the company is VAT-registered. Its company number (CBE) is 0845.096.860.
Where is the registered office of Abbvie?
According to the CBE register, the registered office of Abbvie is in 1300 Wavre.
What is the equity of Abbvie?
At the close of the 2025 financial year, the equity of Abbvie amounts to 182,727,882 €, a solvency of 80.4% of total assets.
How many people work at Abbvie?
213.4 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Abbvie?
The register lists 4 active mandates at Abbvie. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Abbvie
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →